Literature DB >> 26225145

Dual X-Ray Absorptiometry Whole Body Composition of Bone Tissue in Rheumatoid Arthritis - a Cross-Sectional Study.

Claudiu Popescu1, Violeta Bojinca2, Daniela Opris2, Ruxandra Ionescu2.   

Abstract

OBJECTIVES: Previous studies of bone tissue in rheumatoid arthritis (RA) using dual X-ray absorptiometry (DXA) concentrated on regions of interest that were used to diagnose osteoporosis. This study aimed to compare the whole body bone tissue (wbBT) of RA patients with healthy subjects and to identify the RA variables which significantly predict wbBT.
METHODS: The study was cross-sectionally designed to include postmenopausal RA patients and age-matched healthy female controls. All 107 RA patients and all 104 controls underwent clinical examination, laboratory tests and whole body DXA composition, which recorded total and regional bone indices. Non-parametric standard statistical test and regression models after data normalization were used to assess correlations, associations and differences.
RESULTS: Compared to controls, RA patients had significantly lower whole body and regional bone mass (14.9 kg compared to 15.5 kg; p = 0.031). Disease duration (r = -0.402 ; p < 0.001), C-reactive protein (r = -0.279; p = 0.015) and inflammation (2.5% wbBT compared to 2.9%; p = 0.043), radiographic damage (14.3 kg compared to 16.2 kg; p < 0.001), disease activity scores (r = -0.275 ; p = 0.018 for HAQ) are significantly correlated/associated with lower wbBT. Clinical structural damage is associated with lower wbBT and it can significantly predict them (R2 = 0.014; p = 0.001), while glucocorticoid treatment, even in low doses, was associated with lower wbBT percent (2.6% compared to 2.8%; p = 0.045). Treatment with biologics was associated with a lower rate of whole body osteoporosis (0% compared to 22.2%; p = 0.013).
CONCLUSIONS: The main associated factors with the generalized bone loss in female RA patients are disease duration and disease activity. Clinical structural damage is the most powerful predictor of the whole body bone loss. These results suggest a general disturbance of skeletal bone metabolism in RA and could explain a greater risk of fragility fractures of non-central sites (e.g. ribs, tibia, ankles etc.) compared to post-menopause osteoporosis.

Entities:  

Keywords:  bone; rheumatoid arthritis; whole body DXA

Year:  2015        PMID: 26225145      PMCID: PMC4496760     

Source DB:  PubMed          Journal:  Maedica (Buchar)        ISSN: 1841-9038


  21 in total

1.  A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis.

Authors:  L Sinigaglia; A Nervetti; Q Mela; G Bianchi; A Del Puente; O Di Munno; B Frediani; F Cantatore; R Pellerito; S Bartolone; G La Montagna; S Adami
Journal:  J Rheumatol       Date:  2000-11       Impact factor: 4.666

2.  2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Authors:  Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovsky; Frederick Wolfe; Gillian Hawker
Journal:  Ann Rheum Dis       Date:  2010-09       Impact factor: 19.103

3.  Treatment with low-dose prednisolone is associated with altered body composition but no difference in bone mineral density in rheumatoid arthritis patients: a controlled cross-sectional study.

Authors:  I-L Engvall; K Brismar; I Hafström; B Tengstrand
Journal:  Scand J Rheumatol       Date:  2010-11-16       Impact factor: 3.641

4.  Threefold increased risk of hip fractures with rheumatoid arthritis in Central Finland.

Authors:  T M Huusko; M Korpela; P Karppi; V Avikainen; H Kautiainen; R Sulkava
Journal:  Ann Rheum Dis       Date:  2001-05       Impact factor: 19.103

5.  Development of a multi-dimensional health assessment questionnaire (MDHAQ) for the infrastructure of standard clinical care.

Authors:  T Pincus; Y Yazici; M Bergman
Journal:  Clin Exp Rheumatol       Date:  2005 Sep-Oct       Impact factor: 4.473

6.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Authors:  M L Prevoo; M A van 't Hof; H H Kuper; M A van Leeuwen; L B van de Putte; P L van Riel
Journal:  Arthritis Rheum       Date:  1995-01

7.  Changes in body composition after 2 years with rheumatoid arthritis.

Authors:  C Book; M K Karlsson; J-Å Nilsson; K Akesson; L T H Jacobsson
Journal:  Scand J Rheumatol       Date:  2010-09-26       Impact factor: 3.641

8.  Body composition in rheumatoid arthritis.

Authors:  R Westhovens; J Nijs; V Taelman; J Dequeker
Journal:  Br J Rheumatol       Date:  1997-04

9.  Early rheumatoid arthritis and body composition.

Authors:  Christina Book; Magnus K Karlsson; Kristina Akesson; Lennart T H Jacobsson
Journal:  Rheumatology (Oxford)       Date:  2009-07-13       Impact factor: 7.580

10.  Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score.

Authors:  Daniel Aletaha; Valerie P K Nell; Tanja Stamm; Martin Uffmann; Stephan Pflugbeil; Klaus Machold; Josef S Smolen
Journal:  Arthritis Res Ther       Date:  2005-04-07       Impact factor: 5.156

View more
  1 in total

1.  Time-averaged disease activity of rheumatoid arthritis associated with long-term bone mineral density changes.

Authors:  Chung-Yuan Hsu; Jia-Feng Chen; Yu-Jih Su; Ying-Chou Chen; Han-Ming Lai; Shan-Fu Yu; Hsiao-Ru He; Tien-Tsai Cheng
Journal:  Ther Adv Chronic Dis       Date:  2020-12-23       Impact factor: 5.091

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.